TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03747315

Intervention type: OTHER
Intervention: In vitro functional test
Description: Measurement of interleukin-1beta secretion by monocytes and measurement of cell death upon Pyrin inflammasome activation by kinase inhibitor on an additional blood sample (4 ml for children under 12 and 10 ml for children 12 years and older and adults) during a sample for patient care.

Intervention type: OTHER
Intervention: In vitro functional test
Description: Measurement of interleukin-1beta secretion by monocytes and measurement of cell death upon Pyrin inflammasome activation by kinase inhibitor on an additional blood sample (4 ml for children under 12 and 10 ml for children 12 years and older and adults) during a sample for patient care.

Intervention type: OTHER
Intervention: In vitro functional test
Description: Measurement of interleukin-1beta secretion by monocytes and measurement of cell death upon Pyrin inflammasome activation by kinase inhibitor on samples from healthy subjects who donated their blood to the French Blood Establishment.
Study: NCT03075345

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy
Description: Four sessions of the ACT protocol will be psychoeducational in nature, with brief experiential exercises in the class and in-between session practice. It's aim is to allow individuals to be able to sit with difficult experiences (rather than fight against them) and in turn this may allow them to live towards what they value in life.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (dietetic intervention)
Description: Six sessions of a dietetic intervention will be psychoeducational in nature around weight and nutrition, delivered by professionals working in the service.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual (dietetic intervention)
Description: Six sessions of a dietetic intervention will be psychoeducational in nature around weight and nutrition, delivered by professionals working in the service.
Study: NCT02642003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony Stimulating Factor
Study: NCT03014128

Intervention type: OTHER
Intervention: Clinical examination and data processing of questionnaires
Description: xy

Intervention type: OTHER
Intervention: Clinical examination and data processing of questionnaires
Description: xy

Intervention type: OTHER
Intervention: Clinical examination and data processing of questionnaires
Description: xy
Study: NCT04403646

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ARBOX
Description: dry extract of polyphenols (tannins) form quebracho and chestnut 240 mg, B12 vitamin 0.72 µg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Matching placebo, twice-daily administration BID as described for the test product, identical number of tablets as given for ARBOX
Study: NCT00740909

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: A therapy designed to help patients with response prevention skills.
Study: NCT02889198

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Go NAP SACC
Description: Go NAP SACC is a suite of online tools designed to help child care programs improve their nutrition environment. Tools include: self-assessment, goal setting, action planning, and tips and materials. In addition to these online tools, local technical assistance providers offer center directors an orientation on how to use Go NAP SACC and minimal ongoing technical assistance.
Study: NCT03309657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam
Description: This is an observational pharmacokinetic study whereby patients received a single dose of ceftolozane/tazobactam and plasma and cerebrospinal fluid samples were subsequently collected and analyzed to described the pharmacokinetics.
Study: NCT02144480

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive training
Description: The IT group will receive physiotherapy twice daily with longer duration and higher intensity

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: traditional training
Description: usual care: conventional rehabilitation
Study: NCT00754208

Intervention type: DRUG
Group type: OTHER
Intervention: methylphenidate
Description: Starting dose: methylphenidate (immediate-release pill) or Methylin (immediate-release chewable tablet for those unable to swallow pills) 2.5mg Q AM and Q noon. Target dose of 1mg/kg/day. Titration will occur as follows: 5mg Q AM and Q noon, then 7.5mg Q AM and Q noon, then 10mg Q AM and Q noon, as tolerated, not to exceed 30mg per day. Once each child arrives at a stable dose with a good response and good tolerability, they will be converted to the closest Ritalin LA dose, with a target dose of 1mg/kg/day.
Study: NCT03687372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-101
Description: hydrogen peroxide topical solution 45%

Intervention type: OTHER
Group type: OTHER
Intervention: vehicle
Description: vehicle as a topical solution
Study: NCT03891862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valbenazine
Description: vesicular monoamine transporter 2 (VMAT2) inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valbenazine
Description: vesicular monoamine transporter 2 (VMAT2) inhibitor
Study: NCT02309177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study: NCT01698086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation: balance and eye movement exercises
Description: The Experimental group will perform 1-hour supervised intervention sessions 2x/wk for 6-wks, then 1x/wk for 8-weeks, for a total of 20 supervised sessions. The intervention is a progressive vestibular rehabilitation program comprised of balance and eye movement exercises as detailed in our preliminary study report. The balance training includes standing and walking tasks on varied types of compliant surfaces, base of support, head movements, visual input and eye-hand tasks. The tasks will progress from simple to more complex. Eye movement exercises will include voluntary saccadic eye movements and smooth pursuit movements. Vestibulo-ocular eye training will be performed while visually fixating on a stationary object, while moving the head up and down and side to side at various speeds, progressing from sitting to standing on firm and compliant surface. Participants in the Experimental group will be given items of the exercise program to perform as a home exercise program.
Study: NCT04180839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: gaming-related retrieval-extinction
Description: During one training session,participants will first view a 5-min retrieval video containing gaming content and then, 10 minutes later, receive 1-hour of extinction training in which they will be administered four sequences of video, picture and in vivo gaming cues.~The whole training includes 2 training sessions. Participants will receive one training session once a day for two consectutive days.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: nongaming-related retrieval-extinction
Description: During one session,participants will first view a 5-min neutral video and then, 10 minutes later, receive 1-hour of extinction training in which they will be administered four sequences of video, picture and in vivo gaming cues.~The whole procedure includes 2 sessions. Participants will receive one session once a day for two consectutive days.
Study: NCT02469077

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will undergo laboratory evoked thermal pain response testing with: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naloxone
Description: In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will undergo laboratory evoked thermal pain response testing with: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naloxone
Description: In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will undergo laboratory evoked thermal pain response testing with: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each).
Study: NCT03891862

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: non-active dosage form
Study: NCT03946683

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cyberknife for Early Stage Breast Cancer
Description: Utilization of Cyberknife Robotic Radiosurgery as a 5-fraction post-lumpectomy adjuvant radiation treatment in the management of early stage breast cancer
Study: NCT03279549

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine dressing change
Description: Through regular dressing changes to clean the wound, reduce bacterial growth in the wound and protect the wound. In recent years, nano-silver ion gel and dressings are widely used in burns, which effectively reduced the risk of wound infection and beneficial for wound healing. This technique is widely used in clinic.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Limited debridement & Acellular dermal matrix dressing
Description: In the removal of necrotic dermis in the rather not deep principle, as far as possible not damage the normal dermal tissue and skin accessories. This could improve circulation of wounds and improve wound healing. The xenogeneic acellular dermal matrix dressing has a better protective effect on burn wound after debridement. After covering, the wound will remain alive for about two weeks, providing a good microenvironment for wound repair.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Limited debridement & Epidermal cell spraying
Description: In the removal of necrotic dermis in the rather not deep principle, as far as possible not damage the normal dermal tissue and skin accessories. This could improve circulation of wounds and improve wound healing. Epidermal cell spraying technology is a brand new method to rapidly collect epidermal cells from patients themselves and then used on their wounds. The recipient site is 40-80 times than the donor site.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Limited debridement & Basic fibroblast growth factor
Description: In the removal of necrotic dermis in the rather not deep principle, as far as possible not damage the normal dermal tissue and skin accessories. This could improve circulation of wounds and improve wound healing. BFGF is a kind of polypeptide capable of promoting the growth of fibroblasts, and it also promotes the proliferation, differentiation and migration of epidermal cells. Studies have shown that bFGF could significantly improve the healing of burn wounds.
Study: NCT00636194

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bausch & Lomb Multipurpose Solution
Description: daily care of contact lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alcon OptiFree Replenish Multipurpose Solution
Description: daily care for contact lenses
Study: NCT01940315

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rBV A/B
Description: 0.5 mL dose of rBV A/B (40 µg) given at Days 0, 28 ± 5 days, and 182 ± 9 days

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (USP sterile saline for injection)
Description: 0.5 mL dose of Placebo will be given at Days 0, 28 ± 5 days, and 182 ± 9 days
Study: NCT03784092

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: feedback
Description: feedback by electronic pedometers regarding patient mobility while undergoing labor induction
Study: NCT03192540

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will undergo an exercise protocol once a week, for eight weeks. Exercise will be continuous for one hour.
Study: NCT00810082

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActiveStep
Description: ActiveStep™ is a training simulator. The system uses a computer-controlled treadmill to recreate life-like dynamic balance challenges such as slipping and tripping in a safe, controlled environment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physical Therapy for Fall Prevention
Description: Standard physical therapy for fall prevention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Physical Therapy for Fall Prevention
Description: Standard physical therapy for fall prevention
Study: NCT03681795

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Experimental MRI exam and PET scan exam with radiotracer
Description: MRI exam and PET scan exam with radiotracer

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Experimental MRI exam and PET scan exam with radiotracer
Description: MRI exam and PET scan exam with radiotracer
Study: NCT02995733

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PARTICS using QVAR
Description: Patient takes inhaled corticosteroid at the time of rescue inhaler use
Study: NCT03802487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin (SAR439954)
Description: Pharmaceutical form: Tablet~Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-microtracer
Description: Pharmaceutical form: Solution for injection~Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Charcoal
Description: Pharmaceutical form: Granules for suspension~Route of administration: Oral
Study: NCT05550077

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherence Tomography
Description: Intravascular evaluation for vessel wall structure of intracranial atherosclerotic stenosis by application of optical coherence tomography

Intervention type: PROCEDURE
Intervention: Percutaneous transluminal angioplasty and stenting
Description: Percutaneous transluminal angioplasty and stenting will be performed follow the standard or adjusted according to OCT evaluation.

Intervention type: PROCEDURE
Intervention: Percutaneous transluminal angioplasty and stenting
Description: Percutaneous transluminal angioplasty and stenting will be performed follow the standard or adjusted according to OCT evaluation.
Study: NCT04572919

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lateral advancement flap
Description: Patients were randomly assigned to undergo either lateral advancement flap or classic Limberg flap for treatment of non-complicated pilonidal sinus

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: classic Limberg flap
Description: Patients were randomly assigned to undergo either lateral advancement flap or classic Limberg flap for treatment of non-complicated pilonidal sinus
Study: NCT01760018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desflurane group
Description: anesthesia is maintained with desflurane and remifentanil (Desflurane group)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TIVA group
Description: anesthesia is maintained with fresofol and remifentanil (TIVA group).
Study: NCT01232309

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Chitin-Glucan
Description: 3 x 500 mg capsules (tid) = 4.5 mg daily dose

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Chitin-Glucan
Description: 3 x 167 mg capsules (tid) = 1.5 g daily dose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Dose Chitin-Glucan + Olive Extract
Description: 3 x 167 mg capsules (tid) = 1.5 g daily dose (C-G) + 135 mg olive extract

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 x 500 mg capsules (tid)
Study: NCT02524132

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Study: NCT00910637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gestodene/EE Patch (BAY86-5016)
Description: 55 mg ethinyl estradiol \& 2.1 mg gestodene, 21 days for 13 cycles
Study: NCT03580213

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand therapy MCPJ affected
Description: Prevention of oedema, treatment of scar, splinting to maintain or improve extension, exercises, activity of daily living as exercise. Instructions, demonstration and advices.
Study: NCT03677323

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: The patient will have the choice between different environments and the use of this device will remain under the control of the medical team.~The patient will wear the virtual reality device at the time of the completion of the ankle block and will remove it once the nerve puncture is complete.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Droleptan
Description: Venous administration of 1.25 mg of Droleptan
Study: NCT03580213

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand therapy PIPJ affected
Description: Prevention of oedema, treatment of scar, splinting to maintain or improve extension, exercises, activity of daily living as exercise. Instructions, demonstration and advices. Possible additional splint and exercises specifically for the PIPJ extension.
Study: NCT02151019

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: IMRT will be given to some patients to enable comparison of the acute grade 2 GI toxicities compared to those patients receiving their radiotherapy by 3-DCRT
Study: NCT03677323

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Venous administration of 20 mg of Propofol
Study: NCT03219203

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine
Description: Hepatitis B vaccine (20 µg/ml) 1 ml intramuscular injection in single (at 0 month) or 3-dose series (at 0, 1, 6 months)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B vaccine
Description: Hepatitis B vaccine (20 µg/ml) 1 ml intramuscular injection in single (at 0 month) or 3-dose series (at 0, 1, 6 months)
Study: NCT04683289

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: trabeculotomy
Description: performing partial unroofing of the SC and viscoelastic injection into the 2 ostia of the canal. This was followed by connecting the scalemm canal to the anterior chamber

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: trabeculotomy
Description: performing partial unroofing of the SC and viscoelastic injection into the 2 ostia of the canal. This was followed by connecting the scalemm canal to the anterior chamber
Study: NCT02951351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proparacaine
Description: Extra proparacaine will be applied to the conjunctival surface to determine its role in patient experience.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conjunctival culture
Description: Conjunctival cultures will be performed to ensure that the intervention does not interfere with antisepsis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conjunctival culture
Description: Conjunctival cultures will be performed to ensure that the intervention does not interfere with antisepsis.
Study: NCT02792985

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multisensory stimulation protocol
Description: Participation in occupation-based multisensory stimulation (e.g. personal care with aromatic soaps, varying water temperatures and textured sponges, drink preparation of different flavoured beverages) with a variety of different sensory stimuli (e.g. strong smells, different shapes and weights). The participant will receive two individual 30-minute therapy sessions with an Occupational Therapist.~An enriched environment will be set up in the participant´s bedroom. It will include items that provide a range of meaningful sensory stimuli (e.g. familiar personal objects, projection of photos and known places, familiar music). The participant is encouraged to follow a timetable including regular rest breaks through out the day in their room.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control protocol
Description: Retraining of basic activities of daily living or participation in table top tasks and games in an individual 30 minute session or a one hour small group session with an Occupational Therapist.~Minimal changes are made to the participant´s room (e.g. orientation board, photos of family and friends).
Study: NCT03321006

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phonak Audeo B-R 90 hearing aid device (Active)
Description: Hearing aids will be the latest Audeo B-R 90 devices manufactured by Phonak. Full amplification hearing aids will have their gain determined by audiometric profile as per standard clinical practice

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Duloxetine or escitalopram
Description: We opted to allow two potential medication choices so that study participation could be offered to individuals who had previously taken one medication and either not responded or not tolerated it. After 4 weeks if subjects do not meet remission criteria (HRSD≤10), the dose of study medication will be increased to escitalopram 20mg or duloxetine 60mg for the remaining 8 weeks of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine or escitalopram
Description: We opted to allow two potential medication choices so that study participation could be offered to individuals who had previously taken one medication and either not responded or not tolerated it. After 4 weeks if subjects do not meet remission criteria (HRSD≤10), the dose of study medication will be increased to escitalopram 20mg or duloxetine 60mg for the remaining 8 weeks of the study.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Audeo B-R 90 hearing aid device (Sham)
Description: Hearing aids will be the latest Audeo B-R 90 devices manufactured by Phonak. Low amplification hearing aids will be programmed to a hearing threshold of 10dB across all frequencies